Loading organizations...
§ Private Profile · 10355 Science CTR Dr, San Diego, California, 92121, United States
Clinical-stage biopharmaceutical company discovering and developing novel therapeutic antibodies for fibrotic and metabolic diseases.
Bird Rock Bio is a clinical-stage biopharmaceutical company based in La Jolla, California, that develops novel therapeutic antibodies for inflammatory, fibrotic, and metabolic diseases. The firm primarily focuses on advancing nimacimab, a cannabinoid receptor 1 inhibiting antibody designed to treat conditions such as obesity and chronic kidney disease. Operating with a historical headcount of 10 employees, the enterprise secured a $9 million Series C at a $71 million pre-money valuation and a $2.5 million Series D at a $100 million valuation in 2016. The company received financial backing from prominent venture capital firms including 5AM Ventures, Versant Ventures, SR One, and Merck. In August 2023, Skye Bioscience acquired the business in a stock transaction valued at approximately $20 million. Originally launched under the name RuiYi, the organization was founded in 2006 by an undisclosed founding team.
Bird Rock Bio has raised $65.0M across 5 funding rounds.
Bird Rock Bio has raised $65.0M in total across 5 funding rounds.
Bird Rock Bio has raised $65.0M across 5 funding rounds. Most recently, it raised $4.0M Debt in June 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 12, 2014 | $4M Debt Financing | Silicon Valley Bank | — | Announced |
| Mar 1, 2014 | $15M Series B | — | 5AM Ventures, Bain Capital Life Sciences, INKEF Capital, Longwood Fund, OrbiMed, SR ONE, The Column Group, Apposite Capital, Aravis, GlaxoSmithKline, M Ventures, Versant Ventures | Announced |
| May 1, 2009 | $13M Series A | — | 5AM Ventures, Bain Capital Life Sciences, Longwood Fund, OrbiMed, SR ONE, The Column Group | Announced |
| Jan 1, 2009 | $25M Series A | — | 5AM Ventures, Bain Capital Life Sciences, Longwood Fund, OrbiMed, The Column Group | Announced |
| Apr 1, 2008 | $8M Series A | — | 5AM Ventures, Bain Capital Life Sciences, Longwood Fund, OrbiMed, The Column Group | Announced |
Bird Rock Bio is a clinical-stage biopharmaceutical company developing innovative immuno-inflammatory regulators, leveraging biological targets with human proof of mechanism to create novel therapeutic antibodies for significant clinical and commercial differentiation.[1][2][3] It focuses on monoclonal antibodies addressing inflammation-related conditions, such as rheumatoid arthritis and metabolic dysfunction-associated steatotic liver disease (MASLD), with a pipeline including gerilimzumab (targeting IL-6), nimacimab (CB1R modulator), and ATX-3105 for autoimmune diseases; the company raised $80.5M before being acquired by Skye Bioscience in August 2023.[1][4]
Originally known as RuiYi and founded in 2009 in La Jolla, California, Bird Rock Bio targeted medical needs in China and globally through proprietary technologies like the iCAP system, achieving Phase 2 status for some candidates before acquisition, which underscores its growth momentum in biotech prior to integration into a larger entity.[1][3][4]
Bird Rock Bio, formerly RuiYi, was founded in 2009 in La Jolla, California, as a biopharmaceutical venture dedicated to discovering biological treatments for inflammation and related diseases, with an initial emphasis on addressing patient needs in China using innovative platforms.[1][3][4] The company's idea emerged from leveraging validated biological targets, such as cytokines like IL-6, to develop monoclonal antibodies via proprietary tech like the iCAP system, building an expanding portfolio amid early clinical traction.[4]
Pivotal moments included advancing candidates like RYI-008 (gerilimzumab) to Phase 2 for rheumatoid arthritis (later discontinued) and nimacimab for MASLD (pending as of available data), backed by leading biotech investors, culminating in its August 2023 acquisition by Skye Bioscience after raising $80.5M total.[1][4] This trajectory reflects a shift from standalone innovator to strategic asset in a maturing immuno-inflammatory space.
Bird Rock Bio rides the wave of immuno-inflammatory therapies, a booming biotech trend fueled by precision targeting of cytokines and receptors amid rising autoimmune and metabolic disorders like rheumatoid arthritis and MASLD.[1][4] Its timing capitalized on post-2009 advances in antibody engineering and proof-of-mechanism data, aligning with market forces like China's biologics demand and global inflammation drug shortages, influencing the ecosystem by validating targets like IL-6 and CB1R for follow-on innovations.[3][4]
The 2023 acquisition by Skye Bioscience exemplifies consolidation trends, amplifying Bird Rock's contributions to antibody-drug pipelines and bridging U.S.-China biopharma gaps, while competitors like Oligomerix (neurodegenerative focus) highlight its niche in inflammation over broader oncology or CNS plays.[1]
Post-acquisition, Bird Rock Bio's assets like nimacimab and ATX-3105 are poised for Phase advancement under Skye Bioscience, potentially yielding first approvals in metabolic and autoimmune spaces amid escalating demand for targeted biologics.[1][4] Trends like AI-driven target discovery and combo therapies will shape its trajectory, evolving its influence from indie pipeline builder to key player in integrated immuno-modulation platforms. This positions it to redefine inflammation treatment, echoing its founding mission of revolutionary biologics now scaled through strategic partnership.[2][3]
Bird Rock Bio has raised $65.0M in total across 5 funding rounds.
Bird Rock Bio's investors include Silicon Valley Bank, 5AM Ventures, Bain Capital Life Sciences, INKEF Capital, Longwood Fund, OrbiMed, SR One, The Column Group, Apposite Capital, Aravis, GlaxoSmithKline, M Ventures.